Sartorius Stedim Biotech S.A. SRTOY OTC

Sartorius Stedim Biotech S.A. (SRTOY) has shown declining revenue growth over the past 3 years, expanding from $3.5B to $2.9B (average -5.9%/yr). Net income reached $255M, reflecting earnings decline at -20.8%/yr on average. The net profit margin is 9%, which is moderate. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 45.3% (moderate), with a -7.2pp trend over the period. With a $211B market cap and MOAT composite score of 64/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (15/100, Fail) — revenue or earnings are not growing
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 21-year history, the company was profitable in 21 of 21 years — a perfect long-term track record
• INCOME (45/100, Partial) — the company is profitable but margin is below 15%
• MOAT (64/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 44/100 with 1/7 criteria passed.